MPM BioImpact LLC takes a 7.2% position in Forte Biosciences (NASDAQ: FBRX)

Rhea-AI Filing Summary

Forte Biosciences, Inc. ownership filing: MPM BioImpact LLC reports beneficial ownership of 1,000,682 shares of common stock, representing 7.2% of the class as reported in the filing. The filing shows sole voting and dispositive power over these shares. The signature date is 05/15/2026.

Insights

Corporate Governance Analyst

Passive investor discloses a meaningful minority stake with sole control over voting and disposition.

MPM BioImpact LLC reports 1,000,682 shares and 7.2% beneficial ownership, citing sole voting and dispositive authority. The filing is procedural disclosure of holdings under ownership reporting rules and does not itself indicate a change in strategy.

Ownership at this level can influence governance in aggregate with other holders; subsequent filings would be needed to show any active engagement or transactional intent.

Key Figures

Beneficial ownership: 1,000,682 shares Percent of class: 7.2% Filing signature date: 05/15/2026

3 metrics

Beneficial ownership 1,000,682 shares Amount beneficially owned reported in Schedule 13G

Percent of class 7.2% Percent of class reported in Item 4(b)

Filing signature date 05/15/2026 Signature date on the Schedule 13G filing

Key Terms

Schedule 13G, Beneficial ownership, Sole dispositive power

3 terms

Schedule 13G regulatory

"Item 2(a) Name of person filing: MPM BioImpact LLC"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficial ownership regulatory

"Item 4(a) Amount beneficially owned: 1,000,682"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole dispositive power regulatory

"Item 4(c)(iii) Sole power to dispose or to direct the disposition of: 1,000,682"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Forte Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

34962G208

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

MPM BioImpact LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,000,682.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,000,682.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,000,682.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Forte Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 3060 PEGASUS PARK DRIVE, BUILDING 6, DALLAS, TX, 75247.
Item 2.
(a)	Name of person filing: MPM BioImpact LLC
(b)	Address or principal business office or, if none, residence: 399 Boylston Street, Suite 1100 Boston, MA 02116
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 34962G208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,000,682
(b)	Percent of class: 7.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,000,682
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,000,682
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MPM BioImpact LLC

Signature:	Christopher Wolf
Name/Title:	Chief Financial Officer
Date:	05/15/2026

FAQ

What stake did MPM BioImpact LLC report in Forte Biosciences (FBRX)?

MPM BioImpact LLC reported beneficial ownership of 1,000,682 shares, representing 7.2%. The filing states the entity has sole voting and sole dispositive power over these shares, dated 05/15/2026.

Does the Schedule 13G filing show MPM BioImpact will sell or buy more FBRX shares?

The filing reports current holdings and control rights; it does not state any purchase or sale plans. It documents sole voting and dispositive power over 1,000,682 shares as of the signature date.

Who signed the 13G for MPM BioImpact LLC in the Forte Biosciences filing?

The Schedule 13G was signed by Christopher Wolf, who is identified with the title Chief Financial Officer, on 05/15/2026. The filing lists MPM BioImpact LLC as the reporting person.

What does 'sole dispositive power' mean in the FBRX filing?

It means MPM BioImpact LLC alone has the authority to decide how the 1,000,682 shares are transferred or voted. The filing explicitly lists sole voting and sole dispositive powers for those shares.